Bioprosthetics Market Overview
The Bioprosthetics market, which was worth USD 4.42 billion in 2021, is expected to grow to USD 10.11 billion by 2029, with a CAGR of 10.90% from 2022 to 2029. Bioprosthetics are the material derived from humans or other species for medical implantations. Bioprostheses have shown considerable advances over the last few years, as their basic characteristic, they become degraded until their complete elimination in the host body. The global Bioprosthetics market is projected to rise at a significant rate over the forecast period. Several noteworthy factors such as increasing incidence of cardiovascular disorders, such as coronary and peripheral artery diseases, rheumatoid heart disease, and consistently the demand for prolonged relief are anticipated to stimulate the growth of the global Bioprosthetics market in the near future.
Furthermore, the growing aging population indicated with rising degenerative cardiac diseases is further propelling the growth of the Bioprosthetic market. Moreover, the new emergence in technologies with novel innovations has evolved the progress in the field of hybrid tissue-engineered bioprostheses, in which non-biodegradable cultured tissue scaffolds are used. These technological advancements are projected to decrease the morbidity and mortality rate related to heart valve disorders, abdominal wall diseases, orthopedic disorders, and others. This factor is anticipated to intensify the share of the Bioprosthetics market in the years ahead.
On the downside, factors such as the need for multiple surgeries, the threat of infections and incompatibility (tissue rejection), irreversible nature, and the threat of uneven skin tone and scars after surgeries are majorly restraining the growth of the Bioprosthetic market.
Covid-19 Impact on Bioprosthetics Market
In addition, the current Bioprosthetics Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Bioprosthetics Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long-term as well as short-term effect which includes supply shortages, panic buying, and stocking, and regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2021 and its projection up to 2029 is provided in detail in this report.
Bioprosthetics Market Segment Overview
Based on the Application, the Cardiovascular segment held the maximum share of the Bioprosthetics market. The extensive growth of this segment is attributed to the increasing patient count suffering from cardiovascular diseases requiring valve replacement procedures. Additionally, the integration of minimally invasive techniques coupled with the ground-breaking advancements introduced in the second-generation bioprosthetics that are aimed at reducing the number of structural failure cases is projected to offer a boost to the demand for bio-implants over the forecast period. For instance, the arrival of bioprosthetic heart valves has led to reduced demand for open-heart surgeries, this crucial factor contributing to the growth of this segment.
Bioprosthetics Market, By Origin
· Xenogenic (Animal Origin)
· Allogenic (Human Origin)
· Tissue Source (Dermis, Pericardium, Or Intestinal Submucosa)
Bioprosthetics Market, By Type
· Allograft
· Xenograft
· Porcine
· Bovine
Bioprosthetics Market, By Application
· Cardiovascular
· Nephrological
· Orthopedics
· Neurological
· Urogenital
· Ophthalmic
· Others
Bioprosthetics Market Regional Overview
In terms of region, North America accounts for a major share in the global Bioprosthetic market. This can be mainly attributed to the increasing technological innovations and rising cardiovascular and orthopedic procedures in this region. In addition to this, North America is a major market for advanced products manufactured through innovation and transforming bioprosthetic technology. Additionally, the market in the Asia Pacific and Latin America is expected to emerge as a significant region in the overall bioprosthetic market in the upcoming years. The favorable factors such as increasing population, rising incidences of road accidents with high unmet medical needs, and emerging healthcare infrastructure are majorly contributing to the development of the Bioprosthetics market in these regions.
Bioprosthetics Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Bioprosthetics Market Competitor overview
Some key developments and strategies adopted by manufacturers in Bioprosthetics are highlighted below.
· In July 2021, CARMAT, the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announced the first implantation of its bioprosthetic artificial heart, Aeson®, in the United States within the framework of the Early Feasibility Study (EFS).
· In July 2021, A research team from the National University Health System (NUHS) was awarded a translational grant of S$4.9 million (US$3.6 million) from the National Research Foundation Singapore Central Gap Fund to further develop its personalized mitral valve bioprosthesis. Currently, around 500 patients in Singapore and more than 1 million around the world require mitral valve surgery annually.
Bioprosthetics Market, Key Players
· Life Cell Corporation
· Edwards Lifesciences Corporation
· LeMaitre Vascular, Inc.
· CryoLife, Inc.
· Labcor Laboratorios Ltd.
· Maquet Metinge Group
· Organogenesis, Inc.
· Braile Biomedica, Inc.
· Medtronic Plc.
· Humacyte, Inc.
· Aortech International Plc
· JenaValve Technology GmbH
· Sorin Group
· Ethicon, Inc.
· St. Jude Medical, Inc.
The Bioprosthetics market, which was worth USD 4.42 billion in 2021, is expected to grow to USD 10.11 billion by 2029, with a CAGR of 10.90% from 2022 to 2029. Bioprosthetics are the material derived from humans or other species for medical implantations. Bioprostheses have shown considerable advances over the last few years, as their basic characteristic, they become degraded until their complete elimination in the host body. The global Bioprosthetics market is projected to rise at a significant rate over the forecast period. Several noteworthy factors such as increasing incidence of cardiovascular disorders, such as coronary and peripheral artery diseases, rheumatoid heart disease, and consistently the demand for prolonged relief are anticipated to stimulate the growth of the global Bioprosthetics market in the near future.
Furthermore, the growing aging population indicated with rising degenerative cardiac diseases is further propelling the growth of the Bioprosthetic market. Moreover, the new emergence in technologies with novel innovations has evolved the progress in the field of hybrid tissue-engineered bioprostheses, in which non-biodegradable cultured tissue scaffolds are used. These technological advancements are projected to decrease the morbidity and mortality rate related to heart valve disorders, abdominal wall diseases, orthopedic disorders, and others. This factor is anticipated to intensify the share of the Bioprosthetics market in the years ahead.
On the downside, factors such as the need for multiple surgeries, the threat of infections and incompatibility (tissue rejection), irreversible nature, and the threat of uneven skin tone and scars after surgeries are majorly restraining the growth of the Bioprosthetic market.
Covid-19 Impact on Bioprosthetics Market
In addition, the current Bioprosthetics Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Bioprosthetics Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long-term as well as short-term effect which includes supply shortages, panic buying, and stocking, and regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2021 and its projection up to 2029 is provided in detail in this report.
Bioprosthetics Market Segment Overview
Based on the Application, the Cardiovascular segment held the maximum share of the Bioprosthetics market. The extensive growth of this segment is attributed to the increasing patient count suffering from cardiovascular diseases requiring valve replacement procedures. Additionally, the integration of minimally invasive techniques coupled with the ground-breaking advancements introduced in the second-generation bioprosthetics that are aimed at reducing the number of structural failure cases is projected to offer a boost to the demand for bio-implants over the forecast period. For instance, the arrival of bioprosthetic heart valves has led to reduced demand for open-heart surgeries, this crucial factor contributing to the growth of this segment.
Bioprosthetics Market, By Origin
· Xenogenic (Animal Origin)
· Allogenic (Human Origin)
· Tissue Source (Dermis, Pericardium, Or Intestinal Submucosa)
Bioprosthetics Market, By Type
· Allograft
· Xenograft
· Porcine
· Bovine
Bioprosthetics Market, By Application
· Cardiovascular
· Nephrological
· Orthopedics
· Neurological
· Urogenital
· Ophthalmic
· Others
Bioprosthetics Market Regional Overview
In terms of region, North America accounts for a major share in the global Bioprosthetic market. This can be mainly attributed to the increasing technological innovations and rising cardiovascular and orthopedic procedures in this region. In addition to this, North America is a major market for advanced products manufactured through innovation and transforming bioprosthetic technology. Additionally, the market in the Asia Pacific and Latin America is expected to emerge as a significant region in the overall bioprosthetic market in the upcoming years. The favorable factors such as increasing population, rising incidences of road accidents with high unmet medical needs, and emerging healthcare infrastructure are majorly contributing to the development of the Bioprosthetics market in these regions.
Bioprosthetics Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Bioprosthetics Market Competitor overview
Some key developments and strategies adopted by manufacturers in Bioprosthetics are highlighted below.
· In July 2021, CARMAT, the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announced the first implantation of its bioprosthetic artificial heart, Aeson®, in the United States within the framework of the Early Feasibility Study (EFS).
· In July 2021, A research team from the National University Health System (NUHS) was awarded a translational grant of S$4.9 million (US$3.6 million) from the National Research Foundation Singapore Central Gap Fund to further develop its personalized mitral valve bioprosthesis. Currently, around 500 patients in Singapore and more than 1 million around the world require mitral valve surgery annually.
Bioprosthetics Market, Key Players
· Life Cell Corporation
· Edwards Lifesciences Corporation
· LeMaitre Vascular, Inc.
· CryoLife, Inc.
· Labcor Laboratorios Ltd.
· Maquet Metinge Group
· Organogenesis, Inc.
· Braile Biomedica, Inc.
· Medtronic Plc.
· Humacyte, Inc.
· Aortech International Plc
· JenaValve Technology GmbH
· Sorin Group
· Ethicon, Inc.
· St. Jude Medical, Inc.
Report Metric | Details |
Market size available for years | 2022–2029 |
Base year considered | 2021 |
Forecast period | 2022–2029 |
Forecast unit | Value (USD Billion) |
Segments Covered | Origin, Type, Application, and Region. |
Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
Companies covered | Life Cell Corporation,Edwards Lifesciences Corporation,LeMaitre Vascular, Inc.,CryoLife, Inc.,Labcor Laboratorios Ltd.,Maquet Metinge Group,Organogenesis, Inc.,Braile Biomedica, Inc.,Medtronic Plc.,Humacyte, Inc.,Aortech International Plc,JenaValve Technology GmbH,Sorin Group,Ethicon, Inc.,St. Jude Medical, Inc. |
Bioprosthetics Market Study Global Market Analysis, Insights and Forecast, 2020-2027
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Bioprosthetics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Origin
- 5.2.1. Xenogenic (Animal Origin)
- 5.2.2. Allogenic (Human Origin)
- 5.2.3. Tissue Source (Dermis, Pericardium, Or Intestinal Submucosa)
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Cardiovascular
- 5.3.2. Nephrological
- 5.3.3. Orthopedics
- 5.3.4. Neurological
- 5.3.5. Urogenital
- 5.3.6. Ophthalmic
- 5.3.7. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Bioprosthetics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Origin
- 6.2.1. Xenogenic (Animal Origin)
- 6.2.2. Allogenic (Human Origin)
- 6.2.3. Tissue Source (Dermis, Pericardium, Or Intestinal Submucosa)
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Cardiovascular
- 6.3.2. Nephrological
- 6.3.3. Orthopedics
- 6.3.4. Neurological
- 6.3.5. Urogenital
- 6.3.6. Ophthalmic
- 6.3.7. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Bioprosthetics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Origin
- 7.2.1. Xenogenic (Animal Origin)
- 7.2.2. Allogenic (Human Origin)
- 7.2.3. Tissue Source (Dermis, Pericardium, Or Intestinal Submucosa)
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Cardiovascular
- 7.3.2. Nephrological
- 7.3.3. Orthopedics
- 7.3.4. Neurological
- 7.3.5. Urogenital
- 7.3.6. Ophthalmic
- 7.3.7. Others
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Bioprosthetics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Origin
- 8.2.1. Xenogenic (Animal Origin)
- 8.2.2. Allogenic (Human Origin)
- 8.2.3. Tissue Source (Dermis, Pericardium, Or Intestinal Submucosa)
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Cardiovascular
- 8.3.2. Nephrological
- 8.3.3. Orthopedics
- 8.3.4. Neurological
- 8.3.5. Urogenital
- 8.3.6. Ophthalmic
- 8.3.7. Others
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Bioprosthetics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Origin
- 9.2.1. Xenogenic (Animal Origin)
- 9.2.2. Allogenic (Human Origin)
- 9.2.3. Tissue Source (Dermis, Pericardium, Or Intestinal Submucosa)
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Cardiovascular
- 9.3.2. Nephrological
- 9.3.3. Orthopedics
- 9.3.4. Neurological
- 9.3.5. Urogenital
- 9.3.6. Ophthalmic
- 9.3.7. Others
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Life Cell Corporation
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Edwards Lifesciences Corporation
- 10.6. LeMaitre Vascular, Inc.
- 10.7. CryoLife, Inc.
- 10.8. Labcor Laboratorios Ltd.
- 10.9. Maquet Metinge Group
- 10.10. Organogenesis, Inc.
- 10.11. Braile Biomedica, Inc.
- 10.12. Medtronic Plc.
- 10.13. Humacyte, Inc.
- 10.14. Aortech International Plc
- 10.15. JenaValve Technology GmbH
- 10.16. Sorin Group
- 10.17. Ethicon, Inc.